Jpmorgan Chase & CO Axogen, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Axogen, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 18,225 shares of AXGN stock, worth $258,795. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,225
Previous 16,419
11.0%
Holding current value
$258,795
Previous $132,000
0.76%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding AXGN
# of Institutions
136Shares Held
36MCall Options Held
79.1KPut Options Held
500-
Arrow Mark Colorado Holdings LLC Denver, CO5.12MShares$72.7 Million0.49% of portfolio
-
First Light Asset Management, LLC Edina, MN3.34MShares$47.5 Million2.2% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT3.31MShares$46.9 Million2.42% of portfolio
-
Black Rock Inc. New York, NY3.25MShares$46.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.52MShares$35.8 Million0.0% of portfolio
About Axogen, Inc.
- Ticker AXGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 42,283,700
- Market Cap $600M
- Description
- AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...